Scotiabank Begins Coverage on Gain Therapeutics (NASDAQ:GANX)

Scotiabank initiated coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Friday,Briefing.com Automated Import reports. The firm set a “sector outperform” rating and a $12.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, November 25th. Roth Mkm reissued a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Finally, Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.20.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $1.80 on Friday. The company has a market capitalization of $47.75 million, a price-to-earnings ratio of -1.64 and a beta of 0.14. The business has a 50 day moving average of $2.24 and a 200 day moving average of $1.95. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. Gain Therapeutics has a 1-year low of $0.89 and a 1-year high of $4.80.

Institutional Trading of Gain Therapeutics

A number of institutional investors have recently modified their holdings of the company. Sprott Inc. purchased a new stake in Gain Therapeutics in the 4th quarter worth approximately $30,000. Benedict Financial Advisors Inc. purchased a new stake in Gain Therapeutics in the fourth quarter worth $35,000. Bridgeway Capital Management LLC bought a new stake in Gain Therapeutics in the fourth quarter valued at $65,000. Northern Trust Corp increased its position in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after purchasing an additional 39,642 shares during the period. Finally, Marshall Wace LLP bought a new position in Gain Therapeutics in the 4th quarter worth $198,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.